MY E.G. SERVICES BERHAD Registration No. 200001003034 (505639-K) 252 NOTES TO THE FINANCIAL STATEMENTS ʹˢ˥ ˧˛˘ Ѓˡ˔ˡ˖˜˔˟ ˬ˘˔˥ ˘ˡ˗˘˗ ʦʤ ʷ˘˖˘ˠ˕˘˥ ʥʣʥʤ (CONT’D) 49. SIGNIFICANT EVENTS DURING THE FINANCIAL YEAR (CONT’D) (a) (cont’d) On 8 March 2021, the Company had further clarified the following areas of cooperation continue to subsist and have been formalised in the Agreement:- (i) to conduct phase 3 clinical trials of Zhifei’s COVID-19 Vaccine; (ii) to achieve compliance of Halal status requirements to secure Halal certification from the Department of Islamic Development Malaysia (JAKIM); and (iii) to be the exclusive distributor of the COVID-19 Vaccine in Malaysia for a period of 3 years. (b) On 27 January 2021, MLSB, a wholly-owned sub-subsidiary of the Company has made the final payment amounting to RM5,381,795 whereby MLSB has previously requested a temporary extension on the payment period for the remaining lease consideration with Johor Corporation for the land at PLO 59, Tanjung Langsat Industrial Complex in relation to a proposed Tanjung Langsat Foreign Workers’ Accommodation (“FWA”) project. (c) On 29 January 2021, MYEGC announced its participation in a recent Series A financing by Beijing DeepScience Technology Ltd. (“DeepScience”), a leading virtual live streaming, real-time animation and digital human company. (d) On 3 February 2021, MYEGM entered into an Exclusive Distribution Agreement with Rubin Investment Pte Ltd (“Rubin”), a company incorporated and existing under the laws of Singapore, to act as Distributor for COVID-19 Diagnostic Suit of Products (“Products”) from Veredus Laboratories Pte. Ltd. (“Veredus”) in order to promote and sell the said Products in Malaysia. (e) On 19 February 2021, the Company launched Hotel Quarantine Portal SafeQ, an online portal offering an array of hotel accommodation and amenity options available to low risk COVID-19 local patients who wish to undergo mandatory quarantine requirements in more comfortable settings (“SafeQ online portal”). (f) On 25 February 2021, the Company launched the use of deep throat saliva-based testing for the COVID-19 virus in Malaysia with the introduction of an at-home screening service in collaboration with BP Healthcare. The service was available from 1 March 2021 at MYEG’s online portal and was offered at RM150 per test. (g) On 16 March 2021, the Company had proposed to undertake the following proposals:- (i) proposed bonus issue of up to 4,149,122,710 new ordinary shares in MYEG (“Bonus Shares”) on the basis of one Bonus Share for every one existing MYEG Share. Further on 23 August 2021, it was announced that the entitlement date has been fixed on 14 September 2021. Subsequently on 14 September 2021, the Company has issued 3,690,309,821 new ordinary shares pursuant to the bonus issue. The new ordinary shares have been listed and quoted on the Main Market of Bursa Securities effective 15 September 2021, thus marking the completion of the bonus issue. (ii) proposed diversification of existing businesses of MYEG and its subsidiaries to include healthcare related businesses; and (iii) proposed amendment to Constitution of the Company to provide greater clarity, enhance administrative efficiency as well as to ensure consistency with the guidelines which may be issued by the regulations from time to time. (h) On 18 March 2021, MLSB, a wholly-owned sub-subsidiary of the Company acquired 11 units of office located at Lorong Sultan Mohamed 25, Taman IKS PKNS, Bandar Sultan Suleiman, 42000 Pelabuhan Klang, Selangor Darul Ehsan, Malaysia, from the Selangor State Development Corporation for a total consideration of RM4,525,000.
RkJQdWJsaXNoZXIy NDgzMzc=